CoChat

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

Open access

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.

Abstract

SARS-CoV-2 from alpha to epsilon: As battles to contain the COVID-19 pandemic continue, attention is focused on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that have been deemed variants of concern because they are resistant to antibodies elicited by infection or vaccination or they increase transmissibility or disease severity. Three papers used functional and structural studies to explore how mutations in the viral spike protein affect its ability to infect host cells and to evade host immunity. Gobeil et al . looked at a variant spike protein involved in transmission between minks and humans, as well as the B1.1.7 (alpha), B.1.351 (beta), and P1 (gamma) spike variants; Cai et al . focused on the alpha and beta variants; and McCallum et al . discuss the properties of the spike protein from the B1.1.427/B.1.429 (epsilon) variant. Together, these papers show a balance among mutations that enhance stability, those that increase binding to the human receptor ACE2, and those that confer resistance to neutralizing antibodies. —VV

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/science.abi7994

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Geographic distribution and evolution of incidence over time of the SARS-CoV-2 B.1.427/B.1.429 VOC. (A) World map showing the geographic distribution and sequence counts of B.1.427/B.1.429 VOC as of 30 April 2021. (B) Cumulative and individual B.1.427/B.1.429 VOC sequence counts by month. (C to E) Total number of SARS-CoV-2 (gray) and B.1.427/B.1.429 VOC (blue/orange) sequences deposited on a monthly basis worldwide (C), in the United States (D), and in California (E). (F to H) Total number of B.1.427/B.1.429 (F), B.1.429 (G), and B.1.427 (H) sequences deposited by country as of 30 April 2021. Only countries with two or more deposited sequences are shown.
Fig. 1. Geographic distribution and evolution of incidence over time of the SARS-CoV-2 B.1.427/B.1.429 VOC. (A) World map showing the geographic distribution and sequence counts of B.1.427/B.1.429 VOC as of 30 April 2021. (B) Cumulative and individual B.1.427/B.1.429 VOC sequence counts by month. (C to E) Total number of SARS-CoV-2 (gray) and B.1.427/B.1.429 VOC (blue/orange) sequences deposited on a monthly basis worldwide (C), in the United States (D), and in California (E). (F to H) Total number of B.1.427/B.1.429 (F), B.1.429 (G), and B.1.427 (H) sequences deposited by country as of 30 April 2021. Only countries with two or more deposited sequences are shown.CC BY · PubMed Central
Fig. 2. B.1.427/B.1.429 S pseudotyped virus neutralization by vaccine-elicited and COVID-19 convalescent plasma. (A, B, E, and F) Neutralizing Ab titers [mean inhibition dilution (ID50)] shown as pairwise connected [(A) and (E)] or GMT [(B) and (F)] against MLV [(A) and (B)] or VSV [(E) and (F)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Moderna mRNA-1273 vaccine (blue). (C, D, G, and H) Neutralizing Ab titers (ID50) shown as pairwise connected [(C) and (G)] or GMT [(D) and (H)] against MLV [(C) and (D)] or VSV [(G) and (H)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine (red). (I and J) Neutralizing Ab ID50 (I) and GMT (J) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from naïve (blue) and previously infected (red) individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine. “Naïve” indicates vaccinated individuals who had not been previously infected with SARS-CoV-2; “immune” refers to vaccinated individuals who had been previously infected with SARS-CoV-2. (K and L) Neutralizing Ab ID50 (K) and GMT (L) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from convalescent individuals who were infected with WT SARS-CoV-2. Neutralization data shown in (A) to (H) and (I) to (L) were performed using 293T-ACE2 and VeroE6-TMPRSS2, respectively. Data are average of n = 2 replicates.
Fig. 2. B.1.427/B.1.429 S pseudotyped virus neutralization by vaccine-elicited and COVID-19 convalescent plasma. (A, B, E, and F) Neutralizing Ab titers [mean inhibition dilution (ID50)] shown as pairwise connected [(A) and (E)] or GMT [(B) and (F)] against MLV [(A) and (B)] or VSV [(E) and (F)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Moderna mRNA-1273 vaccine (blue). (C, D, G, and H) Neutralizing Ab titers (ID50) shown as pairwise connected [(C) and (G)] or GMT [(D) and (H)] against MLV [(C) and (D)] or VSV [(G) and (H)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine (red). (I and J) Neutralizing Ab ID50 (I) and GMT (J) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from naïve (blue) and previously infected (red) individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine. “Naïve” indicates vaccinated individuals who had not been previously infected with SARS-CoV-2; “immune” refers to vaccinated individuals who had been previously infected with SARS-CoV-2. (K and L) Neutralizing Ab ID50 (K) and GMT (L) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from convalescent individuals who were infected with WT SARS-CoV-2. Neutralization data shown in (A) to (H) and (I) to (L) were performed using 293T-ACE2 and VeroE6-TMPRSS2, respectively. Data are average of n = 2 replicates.CC BY · PubMed Central
Fig. 3. Neutralization by a panel of RBD- and NTD-specific mAbs against SARS-CoV-2 D614 S and B.1.427/B.1.429 S pseudoviruses. (A and D) Neutralization of SARS-CoV-2 pseudotyped VSV carrying D614 (gray) or B.1.427/B.1.429 (orange) S protein by clinical stage RBD mAbs (A) and an NTD-targeting mAb (S2X333) (D). Data are representative of n = 2 replicates. (B and E) Neutralization of SARS-CoV-2 S VSV pseudotypes carrying D614 or B.1.427/B.1.429 S by 34 mAbs targeting the RBD (B) and 10 mAbs targeting the NTD (E). Data are the mean of 50% inhibitory concentration (IC50) values (in nanograms per milliliter) of n = 2 independent experiments. Non-neutralizing IC50 titers were set at 105 ng/ml. (C and F) Neutralization by RBD-specific (C) and NTD-specific (F) mAbs shown as mean IC50 values (top) and mean fold change (bottom) for B.1.427/B.1.429 S (orange) relative to D614 S (gray) VSV pseudoviruses. VIR-7831 is a derivative of S309 mAb (sotrovimab). *VIR-7832 (variant of VIR-7831 carrying the LS-GAALIE Fc mutations) shown as squares. Non-neutralizing IC50 titers and fold change were set to 105 ng/ml and 104, respectively.
Fig. 3. Neutralization by a panel of RBD- and NTD-specific mAbs against SARS-CoV-2 D614 S and B.1.427/B.1.429 S pseudoviruses. (A and D) Neutralization of SARS-CoV-2 pseudotyped VSV carrying D614 (gray) or B.1.427/B.1.429 (orange) S protein by clinical stage RBD mAbs (A) and an NTD-targeting mAb (S2X333) (D). Data are representative of n = 2 replicates. (B and E) Neutralization of SARS-CoV-2 S VSV pseudotypes carrying D614 or B.1.427/B.1.429 S by 34 mAbs targeting the RBD (B) and 10 mAbs targeting the NTD (E). Data are the mean of 50% inhibitory concentration (IC50) values (in nanograms per milliliter) of n = 2 independent experiments. Non-neutralizing IC50 titers were set at 105 ng/ml. (C and F) Neutralization by RBD-specific (C) and NTD-specific (F) mAbs shown as mean IC50 values (top) and mean fold change (bottom) for B.1.427/B.1.429 S (orange) relative to D614 S (gray) VSV pseudoviruses. VIR-7831 is a derivative of S309 mAb (sotrovimab). *VIR-7832 (variant of VIR-7831 carrying the LS-GAALIE Fc mutations) shown as squares. Non-neutralizing IC50 titers and fold change were set to 105 ng/ml and 104, respectively.CC BY · PubMed Central
Fig. 4. CryoEM structure of the SARS-CoV-2 B.1.427/B.1.429 S ectodomain trimer. (A) Structure of the S trimer (surface rendering) bound to the S2M11 and S2L20 Fabs (ribbons) in two orthogonal orientations. SARS-CoV-2 S protomers are colored pink, cyan, and gold, and the S2L20 Fab heavy and light chains are colored dark and light green, respectively, and the S2M11 Fab heavy and light chains are colored dark and light gray, respectively. Only the Fab-variable domains are resolved in the map. N-linked glycans are rendered as dark blue spheres. (B) Magnified view of the S2M11-bound RBD with R452 shown in ball and stick representation. (C) Magnified view of the S2L20-bound NTD with disordered N terminus, supersite β-hairpin, and loop regions shown as dashed lines. (D) Superimposition of the CT-P59–bound SARS-CoV-2 RBD structure (PDB 7CM4) on the SARS-CoV-2 B.1.427/B.1.429 S cryoEM structure showing that R452 would sterically clash with the mAb. (E) Superimposition of the LY-CoV555–bound SARS-CoV-2 RBD structure (PDB 7KMG) on the SARS-CoV-2 B.1.427/B.1.429 S cryoEM structure showing that L452R would sterically clash with the mAb. (F) Superimposition of the S2X333-bound SARS-CoV-2 S structure (PDB 7LXW) on the SARS-CoV-2 B.1.427/B.1.429 S cryoEM structure showing that most of the NTD antigenic supersite epitope residues are disordered. (G) Superimposition of the ACE2-bound SARS-CoV-2 RBD structure (PDB 7DMU) on the SARS-CoV-2 B.1.427/B.1.429 S cryoEM structure showing that L452R points away from the interface with ACE2.
Fig. 4. CryoEM structure of the SARS-CoV-2 B.1.427/B.1.429 S ectodomain trimer. (A) Structure of the S trimer (surface rendering) bound to the S2M11 and S2L20 Fabs (ribbons) in two orthogonal orientations. SARS-CoV-2 S protomers are colored pink, cyan, and gold, and the S2L20 Fab heavy and light chains are colored dark and light green, respectively, and the S2M11 Fab heavy and light chains are colored dark and light gray, respectively. Only the Fab-variable domains are resolved in the map. N-linked glycans are rendered as dark blue spheres. (B) Magnified view of the S2M11-bound RBD with R452 shown in ball and stick representation. (C) Magnified view of the S2L20-bound NTD with disordered N terminus, supersite β-hairpin, and loop regions shown as dashed lines. (D) Superimposition of the CT-P59–bound SARS-CoV-2 RBD structure (PDB 7CM4) on the SARS-CoV-2 B.1.427/B.1.429 S cryoEM structure showing that R452 would sterically clash with the mAb. (E) Superimposition of the LY-CoV555–bound SARS-CoV-2 RBD structure (PDB 7KMG) on the SARS-CoV-2 B.1.427/B.1.429 S cryoEM structure showing that L452R would sterically clash with the mAb. (F) Superimposition of the S2X333-bound SARS-CoV-2 S structure (PDB 7LXW) on the SARS-CoV-2 B.1.427/B.1.429 S cryoEM structure showing that most of the NTD antigenic supersite epitope residues are disordered. (G) Superimposition of the ACE2-bound SARS-CoV-2 RBD structure (PDB 7DMU) on the SARS-CoV-2 B.1.427/B.1.429 S cryoEM structure showing that L452R points away from the interface with ACE2.CC BY · PubMed Central
Fig. 5. The B.1.427/B.1.429 S S13I and W152C mutations lead to immune evasion. (A) Binding of a panel of 11 neutralizing (antigenic site i) and one non-neutralizing (antigenic site iv) NTD-specific mAbs to recombinant SARS-CoV-2 NTD variants analyzed by ELISA displayed as a heatmap. (B) Binding of plasma Abs from vaccinated individuals to recombinant SARS-CoV-2 NTD variants analyzed by ELISA. The mean dilution factor for each mutant was compared by the one-way ANOVA test against WT (*P < 0.05, **P < 0.001). (C to G) Deconvoluted mass spectra of purified NTD constructs, including the WT NTD with the native signal peptide (C), the S13I NTD (D), the S13I and W152C NTD (E), the W152C NTD (F), and the S12F NTD (G). The empirical mass (black) and theoretical mass (red) are shown beside the corresponding peak. An additional 119 Da were observed for the S13I and W152C NTDs, corresponding to cysteinylation of the free cysteine residue in these constructs (as L-cysteine was present in the expression media). The cleaved signal peptide (blue text) and subsequent residue sequence (black text) are also shown based on the MS results. Mutated residues are shown in bold. Cysteines are highlighted in light orange (unless in the cleaved signal peptide), and disulfide bonds are shown as dotted light orange lines between cysteines. Residues are numbered for reference.
Fig. 5. The B.1.427/B.1.429 S S13I and W152C mutations lead to immune evasion. (A) Binding of a panel of 11 neutralizing (antigenic site i) and one non-neutralizing (antigenic site iv) NTD-specific mAbs to recombinant SARS-CoV-2 NTD variants analyzed by ELISA displayed as a heatmap. (B) Binding of plasma Abs from vaccinated individuals to recombinant SARS-CoV-2 NTD variants analyzed by ELISA. The mean dilution factor for each mutant was compared by the one-way ANOVA test against WT (*P < 0.05, **P < 0.001). (C to G) Deconvoluted mass spectra of purified NTD constructs, including the WT NTD with the native signal peptide (C), the S13I NTD (D), the S13I and W152C NTD (E), the W152C NTD (F), and the S12F NTD (G). The empirical mass (black) and theoretical mass (red) are shown beside the corresponding peak. An additional 119 Da were observed for the S13I and W152C NTDs, corresponding to cysteinylation of the free cysteine residue in these constructs (as L-cysteine was present in the expression media). The cleaved signal peptide (blue text) and subsequent residue sequence (black text) are also shown based on the MS results. Mutated residues are shown in bold. Cysteines are highlighted in light orange (unless in the cleaved signal peptide), and disulfide bonds are shown as dotted light orange lines between cysteines. Residues are numbered for reference.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page

Cited by

See all 425

Metadata

Authors
McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., Sprouse, K. R., Agostini, M., Pinto, D., Culap, K., Bianchi, S., Jaconi, S., Cameroni, E., Bowen, J. E., Tilles, S. W., Pizzuto, M. S., Guastalla, S. B., Bona, G., Pellanda, A. F., Garzoni, C., Van Voorhis, W. C., Rosen, L. E., Snell, G., Telenti, A., Virgin, H. W., Piccoli, L., Corti, D., & Veesler, D.
Affiliations
  • University of Washington (US)
  • Vir Biotechnology (Switzerland) (CH)
  • Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • VIR Biotechnology (United States) (US)
  • Vir Biotechnology, San Francisco, CA 94158, USA.
  • Independent physician, 6828 Balerna, Switzerland.
  • Clinica Luganese Moncucco (CH)
  • Clinical Research Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
  • Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
Corresponding author
  • McCallum, Matthew
  • Bassi, Jessica
  • Chen, Alex
  • Walls, Alexandra C.
  • Piccoli, Luca
  • Corti, Davide
  • Veesler, David
Venue
Science
Published
2021-08-06
Volume
373
Issue
6555
Pages
648-654
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W3174747632
Cited by
412
References
90
Citations by year
2026: 12 · 2025: 13 · 2024: 25 · 2023: 56 · 2022: 165 · 2021: 141
FWCI
31.48
Type
journal article
Language
en
Open access
Locations
  • Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Institute of Allergy and Infectious Diseases (DP1AI158186, HHSN272201700059C, U01 AI151698-01)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords
SARS-CoV-2, immune evasion, spike protein mutations, L452R, N-terminal domain, receptor binding domain, neutralizing antibodies, monoclonal antibodies, signal peptide cleavage site, disulfide bonds, mRNA vaccines, convalescent plasma, neutralization titers
MeSH terms
Protein Domains, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Antibodies, Monoclonal, Antibodies, Viral, Antigens, Viral, Humans, Models, Molecular, Mutation, Neutralization Tests, Protein Conformation, Amino Acid Substitution, Cryoelectron Microscopy, Protein Subunits, Protein Interaction Domains and Motifs, Immune Evasion, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.